Lupus News

I always receive phone calls from parents sharing that their child or loved one has been diagnosed with lupus.

For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs and medical devices come from America.

Tenkiller Area Community Organization will hold its annual Thanksgiving Community Dinner at the TACO Building on Mullens Lane in Cookson on Saturday, Nov.

Patients with the disease systemic lupus erythematosus currently have few treatment options, but a new treatment is showing great potential in late-stage testing and could reach the market within the next 18 months.

Systemic lupus is the most common form of the autoimmune disease, lupus , which afflicts about five million people worldwide and causes a slew of symptoms including fever, pain and swelling.

Recognizing lupus symptoms isn't easy for the average person. Lupus symptoms are difficult to discern from other diseases.

Wanda is a writer, humorist, motivational speaker, and founder of L-Bow - she also has lupus.

Human Genome Sciences and GlaxoSmithKline announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA for treating systemic lupus.

Rockville-based Human Genome Sciences, a listed biotechnology company in U.S., announced Monday that its experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.

This story was corrected on Nov. 3, 2009. An explanation of the correction is at the end of the story.

Usually, confirmatory phase 3 trials don't cause 40% gains in a stock. Especially after the first one resulted in a crazy 500%-plus gain.

Second successful phase III trial points to the first new lupus treatment in over 5O years.

Here are some of the latest health and medical news developments, compiled by editors of HealthDay : An experimental lupus drug called Benlysta was effective in its second large clinical trial, and drug makers Human Genome Sciences and GlaxoSmithKline will seek European and U.S. approval of the drug in the first half of 2010.

Drug stocks advanced in early trading Monday, as shares of Human Genome Sciences leaped on the release of more positive Phase III clinical data for its new lupus drug Benlysta.

Human Genome Sciences Inc said on Monday that its experimental lupus drug Benlysta was successful in a late-stage clinical trial, paving the way for approval of the first treatment for the disease in 50 years.

Human Genome closed at $19.97. HGSI's Benlysta, a lupus treatment, is expected to have phase 3 data released on November 2. HGSI November option implied volatility is at 249, December is at 170, January is at 143 and April is at 112, according to Track Data, suggesting large movement.

Human Genome Sciences Inc. narrowed its third-quarter losses by a third, partly by increasing its revenue by 61 percent.

Some ways to play one of Wall Street's hottest stocks. ON MAIN STREET, flipping coins is often used to wager on events that have even outcomes.

Pottery festival: The 13th annual Triad Area Fall Pottery Festival will be from 11 a.m. to 5 p.m. Sunday at the Greensboro Farmers Curb Market, 501 Yanceyville St.

Detailed data from the first Phase III trial of Human Genome Sciences Inc.'s lupus drug Benlysta lived up to expectations, boosting analyst confidence in the outcome of a second Phase III trial to be revealed Nov.